bluuebunny/crossref_metadata_2025_split huggingface dataset:
Gender differences in amplitude spectral area (AMSA) of ventricular fibrillation in patients with out-of-hospital cardiac arrest
Authors: Quilico F , Vicini Scajola L , Gentile F R , Compagnoni S , Baldi E , Aramendi E , Isasi I , Lopiano C , Primi R , Bendotti S , Currao A , Contri E , Palo A , Savastano S 
Published: October 2022

Abstract

Introduction
Ventricular fibrillation (VF) Amplitude Spectral Area (AMSA) is a well-established predictor of successful defibrillation and return of spontaneous circulation (ROSC). Attending to the limited evidence on the topic, gender seems to affect AMSA, and higher values have been reported in females. The aim of this work was to investigate the effect of gender in AMSA values for patients suffering out-of-hospital cardiac arrest (OHCA).

Methods
We enrolled 4619 consecutive OHCA patients from January 2015 to December 2020 in the LombardiaCare Registry. We considered only those subjects with attempted cardio-pulmonary resuscitation (697 patients) and at least one shock delivered. A total of 250 patients were considered (40 F/ 210 M) with 830 shocks (100 F/ 730 M). AMSA values were computed for the ventricular fibrillation in the 2-s pre-shock interval of the ECG recorded by the Corpuls3 defibrillator (Corpuls, Kaufering, Germany).

Results
Female patients were older than male [median (IQR): 70.5 (62–72) vs 67 (55–75) years, p=0.01], with cardiac arrest more frequently at home (84% vs 76%, p=0.003), fewer shocks [2 (1–4) vs 4 (2–7), p=0.004] and higher percentage of success (53% vs 40%, p=0.009). On the contrary, cardiac arrest duration [ 58.7 (31–69) vs 57.6 (41.4–77.3) min, p=0.366] and the rate of ROSC (32% vs 33%, p=0.88) were similar in both groups.
Higher AMSA values were found in female patients [10.3 Hz-mV (6.6–13.5) vs 7.9 Hz-mV (5.2–12.1), p=0.0007]. At a multivariable analysis, after correction for witnessed status, bystanders CPR, amiodarone administration, age and call-to shock time, male sex was found to be independently associated with the probability of having low values of AMSA, below the median value of 8.3 Hz-mV [OR 2.15 (95% CI1.35–3.43), p=0.001].
Despite gender stratification ROC curve analysis confirmed AMSA as a predictor of shock success [AUC-F: 0.75 (95% CI 0.65–0.83), p&lt;0.001; AUC-M: 0.78 (95% CI 0.74–0.81)] and ROSC [AUC-F: 0.69 (95% CI 0.59–0.68), p=0.008; AUCM: 0.84 (95% CI 0.81–0.87)].

Conclusion
Female sex is related to higher AMSA values. As AMSA reflects the energetical status and the ATP levels in the myocardial cells during cardiac arrest, this difference may be due to lower incidence and lower severity of cardiac ischemic disease in women. AMSA remains a valid predictor of both shock success and ROSC for female and male patients. Further investigations are needed to support and comprehend these conclusions.

Funding Acknowledgement
Type of funding sources: None.
Bipolar ablation of refractory ventricular arrhythmias using a novel dedicated adapter. A multicenter study
Authors: Futyma P , Bordignon S , Imnadze G , Peichl P , Seidl S , Kueffer T , Chen S , Zarebski L , Martinek M , Puererfellner H , Kautzner J , Reichlin T , Sommer P , Chun J K R , Schmidt B 
Published: October 2022

Abstract

Background
Bipolar ablation (BA) recently emerged as an alternative for treatment of ventricular tachycardia (VT) and premature ventricular contractions (PVC) refractory to a classic unipolar ablation (UA). Data on the use of available BA systems is lacking.

Purpose
To determine feasibility, safety and efficacy of a novel BA adapter in consecutive patients with refractory VT/PVC undergoing repeat ablations.

Methods
The study group consisted of consecutive patients with VT/PVC after failure of at least one standard UA who underwent redo procedures performed with a support of BA at six European centers. A second ablation catheter was connected in the position of a return electrode using a novel BA adapter.

Results
Between March 2021 and March 2022 a total number of 19 patients after failed ablation attempts underwent redo procedure using a novel BA adapter (17 males, age 61±11, number of prior ablation attempts 2,5±1,6; range 1–7). The main indication for redo ablation was recurrence of frequent PVC (n=10), VT (n=8) or electrical storm (n=1). Fifteen patients underwent combined UA+BA procedure during redo ablation, whereas 4 remaining patients underwent BA only. Two patients required epicardial access. Mean procedural time was 157±77 minutes. The mean BA time was 367±245s (power 32±9W) and mean UA time was 349±290s (power 43±6W). Apart from 1 anticipated AV block there were no major complications. Minor complications included char formation at 8mm tip electrode and steam pop without sequalae in one VT patient. BA+UA led to acute elimination of clinical PVC/VT in 18 patients. In the remaining 1 patient no effect on clinical VT during UA+BA was observed. The follow up lasted 4±3 months. Six (75%) VT patients remained arrhythmia-free and significant PVC burden reduction was achieved in nine (90%) PVC patients during follow-up. One patient treated for electrical storm experienced a single VT episode after 11 months. One patient after initially failed UA+BA underwent successful bipolar reablation after 2 months.

Conclusions
Bipolar ablation of refractory ventricular arrhythmias using a novel dedicated adapter is feasible, seems safe and effective. These encouraging preliminary results need to be confirmed in properly designed prospective trials.

Funding Acknowledgement
Type of funding sources: None.
Long-term toxicity of radiosurgery for ablation of ventricular tachycardia
Authors: Cvek J , Peichel P , Knybel L , Jiravsky O , Sramko M , Hecko J , Neuwirth R , Plasek J , Kautzner J 
Published: October 2022

Abstract

Introduction
There is a rising interest in using radiosurgery to modify arrhythmogenic substrate in patients with recurrent VT. However, data on the safety are still inadequate.

Purpose
This is update of toxicity evaluation based on the compilation from our case series, NIRA-VT and STAR-VT.

Methods
Between 2014 and March 2021, 36 patients (33 male, 3 females; mean age 66±10 years) with structural heart disease (ischemic cardiopathy, dilated cardiopathy or fibroma associated scar) from two electrophysiology centers in the Czech Republic (Trinec, Prague) underwent radiosurgery for recurrent VT.
Radiosurgery was performed after at least one failed catheter ablation for VT. The critical part of the VT substrate was identified by electroanatomic mapping using a combination of voltage mapping, pace mapping, and activation mapping; and it was marked on a contrast-enhanced computer tomography study as a CTV. In NIRA-VT trial, CTV included scar based on PET/CT evaluation. Radiosurgery system with real-time motion tracking using the tip of the electrode of an indwelling defibrillator as a fiducial marker was used. A total radiation dose of 25 Gy was delivered to the ablation target in a single session during free breathing. Radiation-induced toxicity was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Only patients with follow up longer than 6 months were included in long term radiation related side effects evaluation.

Results
The mean CTV and PTV were 26±11 ml and 41±22 ml respectively. No patient exhibited acute (up to 3 months) elevation of troponin, pericardial effusion, or a decrease in left ventricular ejection fraction from baseline. Four patients developed acute mild nausea, which waned after antiemetic drugs. Long-term radiation related side effects were evaluated in 19 patients. Two patients (11%) presented radiological signs of lung fibrosis in small area in close distance from PTV. There was no significant decrease in left ventricular ejection fraction during follow up. Six patients (33%) gradually developed significant progression of known mitral regurgitation after SBRT, two (11%) of them had to undergo mitral valve replacement (grade 4 toxicity). Two cases of esophagitis (12%) were seen with one radiation toxicity related death (grade 5 toxicity) due to the unresectable esophagi-pericardial fistula (6%).

Conclusions
Our data indicate the feasibility of radiosurgery, majority of patients presented no/mild radiation related toxicity and decrease of VT burden. However, we have seen three cases of grade 4,5 toxicity. To further investigate long-term safety and efficacy of radiosuergery for VT, enrolling into a randomized prospective study is in progress.

Funding Acknowledgement
Type of funding sources: Public grant(s) – EU funding. Main funding source(s): European Union's Horizon 2020
Diagnosis of channelopathies affects quality of life and psychological status in patients and relatives
Authors: Berne P , Usai F , Silva E , Onida A , Melis I , Casu G 
Published: October 2022

Abstract

Background
Cardiac channelopathies are a group of inherited cardiovascular diseases with increased risk of sudden cardiac death in structurally normal hearts. The psychological status after their diagnosis has not been thoroughly studied.

Purpose
To establish health-related quality of life (QOL) and emotional response to the diagnosis of channelopathies in a cohort of patients and their families.

Methods
Adult patients with diagnosis of channelopathies and their relatives were eligible. After enrolment they were divided in 3 groups, according to the time of psychological evaluation: At diagnosis (T0), one year (T1), and 2 years after diagnosis (T2). Psychological evaluation was conducted through self-report questionnaires on QOL (SF-12), general anxiety (BAI), depression (BDI-II), perceived stress (PSS-10), post-traumatic stress (IES-R), and protective resilience resources (RSA).

Results
From August 2020 to April 2021, 64 patients (95% Brugada syndrome, 3% long QT syndrome, and 2% catecholaminergic polymorphic ventricular tachycardia) and 41 relatives were enrolled. A control group of 105 healthy subjects, matched to the study group regarding age, gender and level of education, was also enrolled.
Patients at T0 showed increased physical and reduced mental QOL; at T1, reduction of RSA; and at T2, reduction of RSA and increased BAI. A significant percentage of patients referred the occurrence of a traumatic event during their lifetime at T0, T1 and T2 (Figure 1). At T0 relatives presented high PSS-10 and a high proportion of them reported experiencing a traumatic episode during their lifetime. BAI score was high among relatives at T0, T1 and T2, reaching levels of concern 2 years after the diagnosis (Figure 2). Female gender independently predicted MCS-12 in patients at T0.

Conclusions
Diagnosis of channelopathies impact different areas of QOL and the psychological sphere in patients (QOL, resilience, anxiety and occurrence of traumatic events during lifetime) and relatives (anxiety, stress, and occurrence of traumatic events during lifetime), and at different moments after the diagnosis. Female gender was an independent predictor of worse mental QOL in patients at T0. Patients and their families should be involved in psychological counselling and psychoeducational interventions, taking into account their differences and the timing of psychological responses, in order to better support them in adjusting to their new life circumstances.

Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Regione Autonoma della Sardegna
Clinical impact of “minimal” right ventricular pacing on atrial arrhythmias: results from the prospective multi-center worldwide EMERALD study
Authors: Di Cori A , Taggeselle J , Giaccardi M , Degand B , Bernhardt J , Fazi A , Gonzalez Chana B , Olivier A , Clark R , Bongiorni M G 
Published: October 2022

Abstract

Background/Introduction
Unnecessary right ventricular pacing (RVP), typically the result of pacing forced by the atrio-ventricular delay (AVD), can have deleterious effects such as atrial arrhythmias (AA) and heart failure (HF). Previous studies have shown that these increased risks occur when unnecessary RVP exceeds 40%, leading to the development of pacing modes to reduce the amount of unnecessary RVP and minimize these risks.

Purpose
The EMERALD (AssEssment of CoMorbiditiEs & Atrial ArRhythmiA Burden In DuaL-Chamber PaceD Patients) Study was a real-world registry designed to assess the impact of RVP burden on the risk of developing AA. The primary endpoint was the difference in incidence of persistent/permanent AA in subjects with high (&gt;40%) and low (&lt;40%) RVP.

Methods
EMERALD was a non-interventional, prospective, observational, multi-center registry conducted at 186 centers in 12 countries. The study enrolled subjects without a previous history of persistent or permanent AA implanted with a dual-chamber (DR) pacemaker according to ESC or ACC/AHA/HRS guidelines. Devices could be implanted as de-novo therapy, generator replacement or an upgrade in therapy. All implanted devices were approved for commercial use by local regulatory authorities. Programming was left to the investigators' discretion. Subjects were followed for at least 24 months. Persistent/permanent AA was defined as: a) &gt;22 hours/day of AA for &gt;7 consecutive days; b) permanent/persistent AA diagnosed during any follow-up visit; c) an AA-related ablation carried-out; d) a cardioversion performed during any follow-up visit.

Results
Eligible follow-up data were available for n=3477 subjects with a RVP value. The population was nearly evenly split between High RVP (47.7%) and Low RVP (52.3%). In the High RVP group, 11.7% fulfilled at least one criterion for persistent/permanent AA versus 9.1% in the Low RVP group (p=0.006). The primary endpoint was met. A reanalysis of the data was performed first looking at quartiles of %RVP. Based on this, the threshold of RVP was changed from 40% to 1% (High RVP&gt;1%; Low RVP&lt;1%). Using this new RVP threshold, 13.1% of patients in the High RVP group fulfilled at least 1 criterion for persistent/permanent AA versus 3.4% in the Low RVP group (p&lt;0.0001).

Conclusions
The EMERALD Study confirmed the results of previous studies showing that limiting unnecessary RVP to &lt;40% is beneficial in reducing the risk of AA in unselected DR pacemaker patients. Moreover, it showed for the first time that even small amounts of unnecessary RVP (&gt;1%) significantly increases the risk of AAs, underlining the need to target very low RVP with efficient modes to reduce RVP.

Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): MicroPort CRM (Clamart, France)
The effect of leadless pacing on LV and RV systolic function is not inferior to conventional RV pacing
Authors: Duchenne J , Garweg C , Puvrez A , Mao Y , Ector J , Willems R , Voigt J U 
Published: October 2022

Abstract

Introduction
Leadless right ventricular (RV) pacing has been recently proposed as alternative to conventional pacemakers (PM's). While RV pacing with a conventional PM is known to cause deterioration of left ventricular (LV) and RV systolic function over time, the effects of leadless PM's are currently under-explored. In this prospective and randomized study, we hypothesized that the effect of leadless RV pacing over time on both LV and RV systolic function is not inferior to conventional RV pacing.

Methods
Fifty-one age-matched patients with a guideline indication for a PM were prospectively recruited and randomized to undergo implantation of either (i) a leadless PM, or (ii) a conventional PM. Patients underwent echocardiography prior to (BL), and at 6 and 12 months (M6 & M12) after PM implantation. All imaging after implantation was performed during active pacing. Analysis included LV ejection fraction (LVEF), LV global longitudinal strain (GLS), and RV free wall (FW) strain.

Results
Twenty-seven patients were implanted with a leadless PM, while twenty-four received a conventional PM. Median age was 82 (80–87) years. At BL, average LVEF and LV GLS were normal and similar in both groups. At M12, both LVEF (−12%) and LV GLS strain (−5%) decreased significantly in both study groups (ANOVA p&lt;0.0001, see Figure 1). RV FW strain decreased only significantly in patients with conventional PM (−4%; ANOVA p=0.031, see Figure 1; post-hoc test BL vs. M12: p=0.029). None of the tested variables, at none of the time points, showed significant difference between the leadless and conventional PM study groups (all p&gt;0.05). Median pacing percentage was 68.2% and similar in both study groups (at all time-points p&gt;0.05).

Conclusions
Both patients with leadless and conventional PM's demonstrate a decrease in LV and RV systolic function, 12 months after implantation. While LV function decrease was similar between both groups, RV function decrease was most prominent in patients treated with conventional PM's. Our data suggest that leadless pacing is not inferior to conventional pacing with regard to the effect on cardiac function.

Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): Research Foundation Flanders (FWO) post-doc grant
Emergency pacemaker implantation in nonagenarians with complete heart block: is single chamber pacing sufficient?
Authors: Mahtani K , Parker M , Maclean E , Vyas R , Bo Wang R , Roelas M , Zemrak F , Muthumala A , Moore P , Sporton S , Chow A , Monkhouse C 
Published: October 2022

Abstract

Background
In ambulatory patients with complete heart block and preserved sinus node activity (CHBs), dual chamber pacing confers well-established physiological benefits versus single chamber pacing. There is limited evidence as to whether these benefits extend to very frail patients, especially those over 90 years of age.

Purpose
In nonagenarians presenting with emergent CHBs from 2016–2019, we compared the clinical characteristics of patients selected for single versus dual chamber pacemakers (PPM), and evaluated the symptomatic and prognostic implications of these devices.

Methods
Baseline characteristics were discerned from electronic records, and physiological data extracted from serial PPM interrogations. Frailty was quantified according to the Rockwood clinical frailty scale (1–9). Cause of death was provided by the patients' General Practitioner. Cox proportional hazards analysis (HR, 95% CI) examined associations with all-cause mortality and death from congestive cardiac failure (CCF).

Results
168 consecutive patients were included (44.3% Male, Median age: 91 (2) years) and followed-up for 26.9±14.6 months. 22 patients (13.1%) were implanted with single chamber pacemakers (all programmed VVIR); when compared with patients receiving dual chamber devices, these patients had similar median age (93 (3) versus 91 (2) years, p=0.15) and LV systolic function (LVEF: 49.2% ±9.7 versus 50.7% ±10.1, p=0.71), but were more frail (Rockwood scale: 5.2±1.8 versus 4.3±1.1, p=0.004) and more likely to have severe cognitive impairment (27.3% versus 9.2%, p=0.018). Post implant, patients who received single chamber devices had higher average respiratory rates (21.3±2.4 breaths per minute versus 17.5±2.6 breaths per minute, p=0.002), lower average heart rates (65.5±10.1 bpm versus 71.9±8.6 bpm, p=0.002), and lower daily activity levels (0.57±0.3 hours of activity versus 1.5±1.1 hours of activity, p=0.016) than those with dual chamber devices. Death from CCF was more common in patients receiving single chamber devices (40.9% versus 6.2%, log rank p&lt;0.0001); this association persisted when adjusting for age, frailty and cognitive impairment (adjusted HR: 6.2 (2.2–17.3, p=0.0005). However, in this age group, single chamber pacing was not independently associated with all-cause mortality when compared with dual chamber pacing (adjusted HR: 1.9 (0.95–3.6, p=0.07).

Conclusions
In nonagenarians with CHBs, dual chamber pacing was associated with improved symptomatic outcomes and a reduced risk of death from CCF, but did not affect all-cause mortality when compared with single chamber pacing.

Funding Acknowledgement
Type of funding sources: None.
Chronic outcomes of leadless vs transvenous single chamber ventricular pacemakers in high-risk subgroups
Authors: Boveda S , Higuera L , Longacre C , Wolff C , Wherry K , Stromberg K , Hinnenthal J , Bockstedt L , El-Chami M 
Published: October 2022

Abstract

Background
The Micra leadless pacemaker (LP-VVI) has been shown to have lower chronic complications and device-related reinterventions compared to transvenous ventricular pacemakers (TV-VVI) in a large, real-world population. This study compares the complication and reintervention rate in subgroups with comorbidities associated with higher risk of pacemaker complications and hypothesized to benefit from leadless pacing.

Methods
The longitudinal Micra Coverage with Evidence Development (CED) Study compared the outcomes of Medicare patients receiving LP-VVI to those receiving a TV-VVI in the US. Patients in the Micra CED study were included in this study if they had a diagnosis of chronic kidney disease Stages 4–5 (CKD45), end-stage renal disease (ESRD), malignancy, diabetes, tricuspid valve disease (TVD), or chronic obstructive pulmonary disease (COPD) on any administrative claim in the 12 months prior to pacemaker implant. A pre-specified set of complications and system reinterventions were identified using the relevant diagnosis and procedure codes. Adjusted and unadjusted Fine-Gray competing risks models were used to compare reinterventions and complications between LP-VVI and TV-VVI patients within each subgroup. All results were adjusted for multiple comparisons using a Bonferroni correction. An ad-hoc comparison of a composite endpoint of select reinterventions (system replacement, removal, revision, and lead reinterventions) and device complications was also conducted.

Results
The sample size of patients in each subgroup ranged from 2,032 patients with ESRD to 11,936 patients with diabetes. The percent of LP-VVI patients in each subgroup ranged from 44.0 in the TVD subgroup to 74.9 in the ESRD subgroup. Compared to patients implanted with a TV-VVI, patients with a LP-VVI with malignancy, diabetes, TVD, and COPD had significantly fewer complications (Table 1; Malignancy, HR 0.68, [0.48–0.95]; Diabetes, HR 0.69, [0.53–0.89]; TVD, HR 0.60 [0.44–0.82]; COPD, HR 0.73, [0.55–0.98]). LP-VVI patients with diabetes, TVD, and COPD also had lower rates of reintervention (Table; Diabetes, HR 0.58, [0.37–0.89]; TVD, HR 0.46 [0.28–0.76]; COPD, HR 0.51, [0.29–0.90]). LP-VVI patients with malignancy, diabetes, TVD, and COPD had lower rates of the combined endpoint of device complications and select reinterventions (Table; Malignancy, HR 0.52, [0.32–0.83]; Diabetes, HR 0.52, [0.35–0.77]; TVD, HR 0.44 [0.28–0.70]; COPD, HR 0.55, [0.34–0.89]).

Conclusions
In a real-world study of US Medicare patients, the leadless pacemaker was associated with lower rates of chronic complications and reinterventions at 2 years compared with TV-VVI pacing in several high-risk subgroups.

Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Medtronic